Loading
Anhedonia / Melancholic Depression / Left DLPFC iTBS · Interventional Study
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective, sham-controlled trial of dual-target intermittent theta burst stimulation (iTBS) to the dorsolateral prefrontal cortex and orbitofrontal cortex for treatment of anhedonia in major depression. The study is currently recruiting and has not yet reported results; it will measure depression severity, remission, and response rates via MADRS, along with reward-circuit functional connectivity changes.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Major Depression, Anhedonia, Melancholic Depression, Theta Burst Stimulation; age from 18 Years; to 45 Years. Intervention: Left DLPFC + OFC iTBS Group; Left DLPFC iTBS Group. Compared with: Sham dual-target iTBS using dedicated sham coil.. n = 60. 1 site: China.
This is a prospective, sham-controlled trial of dual-target intermittent theta burst stimulation (iTBS) to the dorsolateral prefrontal cortex and orbitofrontal cortex for treatment of anhedonia in major depression. The study is currently recruiting and has not yet reported results; it will measure depression severity, remission, and response rates via MADRS, along with reward-circuit functional connectivity changes.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Once results are available, this trial will address whether targeting dual reward-circuit nodes (DLPFC and OFC) with iTBS offers superior anhedonia improvement compared to single-target stimulation and sham. The functional connectivity endpoints may clarify mechanism of action.
This is a registry record of a recruiting interventional study with no results posted; the design compares dual-target to single-target iTBS and sham, but outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial will address whether targeting dual reward-circuit nodes (DLPFC and OFC) with iTBS offers superior anhedonia improvement compared to single-target stimulation and sham. The functional connectivity endpoints may clarify mechanism of action.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07813169). This is a study registration, not published results. Lead sponsor: Guo Wenbin. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Major Depression, Anhedonia, Melancholic Depression, Theta Burst Stimulation. Interventions: DEVICE: Left DLPFC + OFC iTBS; DEVICE: Left DLPFC iTBS. Primary outcome measures: Total score of Montgomery-Åsberg Depression Rating Scale (MADRS) , *Baseline; * Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.; Remission Rate of Montgomery-Åsberg Depression Rating Scale (MADRS) scores , * Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.; Response Rate of Montgomery-Åsberg Depression Rating Scale (MADRS) scores , * Day 2- Day 6 (every treatment day); *1 week post-treatment; *4 weeks post-treatment; *8 weeks post-treatment.. Brief summary: The goal of this clinical trial is to learn if the proposed intermittent theta burst stimulation (iTBS) protocol can effectively improve anhedonia symptoms in depressed patients. The stimulation targets in our protocol include (1) dual-target stimulation at the left dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC). (2) single-target stimulation at the left DLPFC. The main questions it aims to answer are: * Whether iTBS of dual-target stimulation (left DLPFC and OFC) can improve the symptoms of anhedonia and better than single-target stimulation at the left DLPFC? * Whether iTBS of the dual targets of left DLPFC and OFC can improve the symptoms of anhedonia by correcting the abnormal functional connectivity of DLPFC-NAc and OFC-sgACC, regulating the functional abnormalities of NAc and sgACC, and indirectly repairing the overall dysfunction of the reward circuit. * Researchers will compare dual-target stimulation to single-target stimulation and sham dual-target stimulation (a dedicated sham coil is utilized which produces an identical audible click and physical sensation) to see if the proposed iTBS protocol works to treat anhedonia. Participants will: * Take 6 sessions of dual-target iTBS or single-target iTBS every day, for 5 consecutive days. * Visit our hospital at 1 week, 4 weeks, and 8weeks after the iTBS treatment completion, for clinical evaluation and brain image examination.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.